首页> 美国卫生研究院文献>Open Forum Infectious Diseases >Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label Controlled Clinical Phase II Trial
【2h】

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label Controlled Clinical Phase II Trial

机译:修改后的痘苗安卡拉-巴伐利亚北欧天花疫苗在未接种痘苗和有经验的人类免疫缺陷病毒感染者中的安全性和免疫原性:一项开放标签受控的临床II期试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundFirst- and second-generation smallpox vaccines are contraindicated in individuals infected with human immunodeficiency virus (HIV). A new smallpox vaccine is needed to protect this population in the context of biodefense preparedness. The focus of this study was to compare the safety and immunogenicity of a replication-deficient, highly attenuated smallpox vaccine modified vaccinia Ankara (MVA) in HIV-infected and healthy subjects.
机译:背景技术第一代和第二代天花疫苗是禁止感染人免疫缺陷病毒(HIV)的个体的。在生物防御准备工作的背景下,需要一种新的天花疫苗来保护这一人群。这项研究的重点是比较在艾滋病毒感染和健康受试者中复制缺陷型,高度减毒的天花疫苗修饰牛痘安卡拉(MVA)的安全性和免疫原性。

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号